Lead Product(s): IBI302
Therapeutic Area: Ophthalmology Product Name: IBI302
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
The study demonstrated good safety and tolerability of IBI302. One week after administration, improved vision and reduction of retinal edema were observed.